Geode Capital Management LLC Has $10.24 Million Holdings in Altimmune, Inc. (NASDAQ:ALT)

Geode Capital Management LLC lifted its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 4.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,668,004 shares of the company’s stock after buying an additional 74,194 shares during the quarter. Geode Capital Management LLC owned about 2.35% of Altimmune worth $10,244,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ALT. Bellevue Group AG increased its holdings in Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after purchasing an additional 263,660 shares during the last quarter. Barclays PLC grew its holdings in shares of Altimmune by 93.0% in the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after buying an additional 75,064 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Altimmune by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after buying an additional 4,772 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after buying an additional 335,444 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in Altimmune by 318.6% during the third quarter. BNP Paribas Financial Markets now owns 42,140 shares of the company’s stock worth $259,000 after acquiring an additional 32,072 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Price Performance

ALT stock opened at $7.21 on Thursday. The stock has a market capitalization of $512.81 million, a P/E ratio of -4.65 and a beta of 0.15. Altimmune, Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.84. The business has a 50-day moving average of $8.04 and a 200-day moving average of $7.16.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter. During the same period last year, the company earned ($0.39) EPS. Equities analysts expect that Altimmune, Inc. will post -1.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Thursday, November 14th. UBS Group initiated coverage on Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Altimmune has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.